Last reviewed · How we verify
ALKS 33-BUP
At a glance
| Generic name | ALKS 33-BUP |
|---|---|
| Also known as | ALKS 33-BUP: RDC-0313 + buprenorphine. |
| Sponsor | Alkermes, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine (PHASE1)
- ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALKS 33-BUP CI brief — competitive landscape report
- ALKS 33-BUP updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI